Biodistribution of 111in-DTPA-D-Phe1-octreotide in tumor-bearing nude mice: influence of amount injected and route of administration.

[1]  E. P. Krenning,et al.  Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients , 1993, European Journal of Nuclear Medicine.

[2]  M. Sautter‐Bihl,et al.  Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue , 1993, European Journal of Nuclear Medicine.

[3]  E. Krenning,et al.  New advances in peptide receptor radionuclide therapy. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  W. Oyen,et al.  Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. , 2001, European journal of nuclear medicine.

[5]  Eva Forssell-Aronsson,et al.  Intraoperative tumour detection using 111In-DTPA-D-Phe1-octreotide and a scintillation detector , 2001, European Journal of Nuclear Medicine.

[6]  S. Weiner,et al.  End-stage renal disease after treatment with 90Y-DOTATOC , 2001, European Journal of Nuclear Medicine.

[7]  Eva Forssell-Aronsson,et al.  Biokinetics of 111In-DTPA-D-Phe(1)-octreotide in nude mice transplanted with a human carcinoid tumor. , 2001, Nuclear medicine and biology.

[8]  C. Beglinger,et al.  Preclinical Comparison in AR4-2J Tumor-Bearing Mice of Four Radiolabeled 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid-Somatostatin Analogs for Tumor Diagnosis and Internal Radiotherapy. , 2000, Endocrinology.

[9]  B. Eriksson,et al.  Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors. , 1999, Nuclear medicine and biology.

[10]  R. Herrmann,et al.  Yttrium-90 DOTATOC: first clinical results , 1999, European Journal of Nuclear Medicine.

[11]  Eva Forssell-Aronsson,et al.  Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  Eva Forssell-Aronsson,et al.  Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  Eva Forssell-Aronsson,et al.  Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide. , 1996, British Journal of Cancer.

[14]  R. Valkema,et al.  Somatostatin receptor: scintigraphy and radionuclide therapy. , 1996, Digestion.

[15]  T. Visser,et al.  Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  A. Chiti,et al.  Indium-111-DTPA-octreotide Scintigraphy Modulation by Treatment with Unlabelled Somatostatin Analogue in Smali-Cell Lung Cancer , 1995, Tumori.

[17]  Eva Forssell-Aronsson,et al.  Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  Eva Forssell-Aronsson,et al.  Clinical efficacy of octreotide scintigraphy in patients with midgut carcinoid tumours and evaluation of intraoperative scintillation detection , 1994, The British journal of surgery.

[19]  M. Crecco,et al.  Somatostatin receptors in meningiomas: a scintigraphic study using 111In-DTPA-D-Phe-1-octreotide. , 1993, Nuclear medicine communications.

[20]  E. Krenning,et al.  Octreotide scintigraphy for the detection of paragangliomas. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  T. Visser,et al.  In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats. , 1991, Life sciences.